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ABSTRACT 
 
 
 Background. Thyroid cancer is the most common endocrine malignancy. The current 
standard of diagnosis, fine needle aspiration biopsy (FNAB) yields indeterminate results 
for approximately 10–25% of biopsies, necessitating thyroidectomy for diagnosis. Elastic 
scattering spectroscopy (ESS) is a minimally invasive optical biopsy technique that is 
sensitive to cellular and subcellular morphological features. We hypothesized that it was 
feasible to use ESS in vivo to improve our ability to preoperatively differentiate benign 
from malignant thyroid nodules.  
vi 
Methods. Under an IRB approved protocol, we collected ESS data from patients 
undergoing thyroid FNAB using our miniaturized integrated ESS/biopsy probe. Spectral 
findings were compared to cytology.  
Results. 108 patients enrolled, 5 patients were excluded due to procedural and 
mechanical issues. Data from 103 patients was submitted for analysis. Initial evaluation 
of spectra data demonstrates adequacy and comparability of the miniaturized probe to the 
prior full-size ESS fiber construct.  
Conclusion. Performing a clinical trial using a miniaturized integrated ESS/biopsy probe 
in vivo is feasible and acceptable to patients. Both spectral data and cytologic material are 
adequate in the majority of patients. With further accrual and analysis, this ESS device 
may provide cost-effective, real-time, and operator independent assessment of thyroid 
nodules. 
vii 
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 1 
INTRODUCTION 
The Normal Function of the Thyroid Gland 
 The thyroid gland, also referred to as the thyroid, is anatomically located in the 
neck, just below the laryngeal prominence, or what’s more commonly referred to as the 
“Adam’s apple.”  The thyroid is a bi-lobed, butterfly-shaped organ that is connected by 
an isthmus that wraps around the larynx. 
 The thyroid has a wide range of functions in the human body, and is one of the 
largest endocrine glands. Thyroid functions are critical in controlling the body because 
the thyroid regulates metabolic rates, proteins, and other hormones in the body. The main 
products of the thyroid gland are two hormones: triiodothyronine (T3) and thyroxine (T4). 
These hormones principally affect the regulation of metabolism within the body.  
 The production of T3 and T4 is regulated by another hormone in the body, thyroid 
stimulating hormone (TSH). There is a negative-feedback loop between the amounts of 
TSH and T4 production to regulate normal body functions. 
 
Thyroid Disorders 
 There are three main thyroid disorders: 
1) Hyperthyroidism – an overactive thyroid 
2) Hypothyroidism – an underactive thyroid  
3) Thyroid Nodule – a thyroid neoplasm 
Hyperthyroidism is caused from an overproduction of the main thyroid hormones, 
T3 and T4. A lack of the negative feedback mechanism which would normally inhibit the 
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production of thyroid hormones is typically present. Hypothyroidism occurs when not 
enough T3 and T4 is naturally produced by the body. A thyroid nodule indicates a thyroid 
neoplasm, but is usually found to be benign
1
. All three of these thyroid disorders may 
present with an enlarged thyroid, otherwise referred to as a goiter.  
 
Thyroid Nodules 
At 60 years of age, approximately 50% of the population have at least one thyroid 
nodule.
2
 The clinical spectrum of a presenting thyroid nodule can range from a small, 
singular incidental nodule, or a large, symptomatic, pressure-inducing mass that can take 
up the near entirety of a thyroid lobe. 
 
Thyroid Cancer 
Approximately 5% of thyroid nodules
1
 are found to be malignant. There are four 
types of thyroid cancer: 
1) Papillary Thyroid Cancer 
2) Follicular Thyroid Cancer 
3) Medullary Thyroid Cancer 
4) Anaplastic Thyroid Cancer 
Papillary thyroid cancer (PTC) is by far the most common of all thyroid cancers, 
occurring in approximately 80% of the cases.
3
 Females are three times as likely to be 
diagnosed with PTC and it is usually not an aggressive cancer. Diagnosis of this 
particular form of cancer typically occurs between the ages of 30 and 50 years of age.
3
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Follicular thyroid cancer (FTC) makes up approximately 15% of all thyroid 
cancers.
3
  Just like PTC, females are three times more likely to be diagnosed with this 
particular cancer. This particular type of cancer can be more aggressive, especially in 
older patients. FTC is typically diagnosed in individuals from 40 to 60 years of age.
3
  
Medullary thyroid cancer (MTC) occurs in approximately 10% of all thyroid 
cancers.
3
 This form of thyroid cancer is found to have an incidence equal in the female 
and male population, and is found to have a 50% five-year survival rate for stage IV 
cancer. MTC is often diagnosed in patients between 40 and 50 years of age.
3
 
Anaplastic thyroid cancer (ATC) is rare, occurring in less than 5% of thyroid 
nodules.
3
 It is found to have a higher occurrence in females and is the most invasive and 
aggressive form of thyroid cancer. The five-year survival rate with ATC is approximately 
7%, and is typically diagnosed in patients of the age of 65.
3
   
Thyroid cancer is the most common form of endocrine malignancy in the United 
States. An estimated 60,000 new cases of thyroid cancer will be diagnosed in 2013.
4
 
Incidence rates of thyroid cancer have been growing by 7% each year.
5
  These growing 
rates of thyroid cancer may be due to advancements in imaging techniques such as neck 
ultrasongraphy.
6,7
 With an increase in incidence, a stable mortality rate has been seen in 
thyroid cancer.
8
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Diagnosing Thyroid Cancer 
Current state-of-the-art technology in endocrinology utilizes a diagnostic test 
called a fine needle aspiration (FNA) biopsy in order to diagnose a thyroid nodule to 
determine whether the tissue is malignant or benign.
9
 A FNA is comprised of a non-
sterile procedure in which a patient has a series of biopsy needles inserted into their 
thyroid in accordance with the Bethesda standard.
10
 Each needle is used to collect cells 
from the thyroid, and those cells are then sent to a local pathology process where a 
pathologist will analyze the cells in a cytology report. After three to five days, the cells 
will be placed in one of four categories: benign, indeterminate, insufficient or malignant. 
The following criteria were depicted for categorizing which cytology results were placed 
in each of the four categories of a fine needle aspiration biopsy (FNAB). The table is 
reprinted below for convenience. 
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Table 1: A table from the Bethesda System for Reporting Thyroid Cytopathology. The 
table describes the recommended diagnostic criteria for each category of FNA cytology. This 
figure is taken from Ali et al., 2009. 
 
 
 The benign category of cytology is by far the most common.
9
 A graph below 
demonstrates the average findings of the FNA biopsy. 
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Figure 1: A graph demonstrating the typical occurrence of each of the four main 
categories of a thyroid FNA biopsy.  
 
 The diagnostic accuracy of a FNA not only depends on the clinical sensitivity of 
the test, but also on the administrator. The insufficient category of FNA biopsy is a 
disputed area in cytological diagnosis of patients with thyroid lesions, because there are 
inherent similarities in cells under a light microscope.
11
 It has been found that by 
skillfully applying the techniques of an FNA biopsy, in conjunction with the recovery of 
an adequate sample, and a decreased level of interpretive errors, the number of patients 
diagnosed with an indeterminate thyroid nodule can be decreased.
11
 
Risk management of a thyroid nodule is guided by the results of a FNA biopsy. 
Below is the standard of care associated with the results of a thyroid biopsy. 
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Table 2: A table from the Bethesda System for Reporting Thyroid Cytopathology. The 
table is shown here for reference in determining the typical classification of a FNA biopsy, its 
risk of malignancy, and the typical management used with each classification. This figure is taken 
from Ali et al., 2009. 
 
 
For an indeterminate biopsy, the patient undergoes surgery for therapeutic 
reasons. Over 66% of thyroid surgeries are done simply for diagnostic purposes.
10
 FNA 
biopsy is a great screening test for cancer, but has a rather high rate of false positives 
(indeterminates) which leads to a high number of diagnostic surgeries.
9
 If there was a 
way to take out the margin of error in a FNA biopsy, and provide a more accurate 
diagnosis of thyroid cancer, thousands of dollars in surgical costs could be saved, and an 
increased quality of life could be achieved for the patient. 
 
Elastic Scattering Spectroscopy 
Elastic Scattering Spectroscopy (ESS) is an optical imaging technique which uses 
broadband light to take measurements. The light is in the visible spectrum from 300 – 
800 nanometers (nm) and is non-ionzing with no known negative side effects.
12
 ESS has 
been used in other organs and tissues in the body including, but not limited to the 
esophagus, oral cavity lesions, breast tissue and colonic polyps.
13–23
 In all of these tissues, 
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ESS has found to accurately distinguish benign from malignant spectra. ESS is capable of 
providing an objective assessment of tissue that is user independent, and does not require 
the insight of a pathologist. ESS also has the additional benefits of being portable, and is 
capable of taking measurements in real-time.  
ESS works by emitting a point measurement. A graphic below depicts the basic 
functions of ESS.  
 
Figure 2: A graphic demonstrating the scattering of light upon interaction with a tissue of 
interest. In this case, the tissue is the thyroid. 
 
A pair of fiber optics are placed in contact with a tissue of interest, in this case, 
the thyroid. A light source then emits a photon which travels through a fiber optic and 
interacts with the thyroid. In the tissue the photon does one of two things: it is either 
absorbed into the tissue in which case we never see it again; or the photon is scattered 
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about in the tissue. In the case in which the photon is scattered, eventually a photon will 
reach a second fiber optic, deemed the detector fiber, which carries the photon back to a 
spectrometer where the photon is detected. The photon carries with it information about 
its traveled path, and when compiled and displayed on a computer, this displays a 
spectrum. The spectrum is a visual representation of the matter that the photon traveled 
through. This spectrum represents that point measurements that ESS took, and is directly 
affected by the size and density of the organelle with which the photon interacted.  
ESS is capable of performing an “optical biopsy” because this optical method is 
sensitive to most of the features that pathologists look for under the microscope. Cellular 
and sub-cellular components like the nucleus, nucleolus, and mitochondria are 
represented and accounted for in the ESS optical spectrum. Through studying ESS in 
other organs and tissues it has been found that ESS is sensitive to both cellular and 
subcellular morphological features and therefore features associated with malignant 
transformation are detected by ESS.
13
   
FNA is a great screening tool for malignant nodules in the thyroid and has a very 
high sensitivity for malignant thyroid tissue.
24
 However, as seen in figure 1, 35% of 
thyroid nodules will undergo thyroid surgery, even though only 5% of those nodules 
harbor a malignant tissue. The majority of thyroidectomies and lobectomies are done 
purely for diagnostic reasons, because of low specificity and positive predictive values of 
the current state-of-the-art diagnostic tool in endocrinology, FNA biopsy.
25
 
In other human organs and tissues, it has been found that ESS has a high 
specificity when detecting benign from malignant tissue. It is therefore proposed in this 
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research study that we integrate FNA biopsy with an ESS probe in order to create the 
ideal diagnostic tool for detecting thyroid cancer. We hypothesized that an integrated 
ESS biopsy syringe will minimize the amount of diagnostic surgeries done on the thyroid, 
especially for patients who have an indeterminate result from an ordinary FNA.  
In order to test this hypothesis that ESS would have a high specificity in detecting 
benign from malignant thyroid tissue, a small ex vivo clinical trial was conducted at 
Boston Medical Center (BMC) in Boston, MA. The clinical trial consisted of 36 thyroid 
samples which were measured with ESS within ten minutes of surgical removal. The 
study revealed that ESS had a 95% specificity with this small sample size.
24
 
 Using this ex vivo study as motivation, a larger in vivo validation study was 
organized to confirm the assumption set forth in the ex vivo trial and see if the findings 
would be consistent if studied in perfused tissue.  
The study prompted some major design changes from the probe used in the ex 
vivo clinical trial. The optical probe had to be engineered around the concentric constrain 
of a 23-gauge needle typically used during a FNA biopsy. This meant the optical 
geometry of the probe had to be changed, and the diameter of the fiber optics used for the 
emission and detection of a photon had to be reduced. With the reduction in size came a 
quadratic reduction in cross-sectional area. This meant that in order to emit the same 
intensity light used in the ex vivo study, a longer acquisition time had to be used to 
acquire the measurements. Although longer, both the larger ESS probe used in the ex vivo 
study and the smaller, in vivo optical probe took measurements in under one second.   
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SPECIFIC AIMS 
The specific aims of this project can be broken up into four main objectives: 
1) Conduct an in vivo clinical trial 
2) Miniaturize the ESS probe for a 23 gauge needle  
3) Co-register ESS readings with cytology and histology 
4) Use data to discriminate benign & malignant nodules through automated feature 
analysis 
This project is an expansion of the work done by Suh et al who has established 
that an ex vivo model of this probe can accurately distinguish between benign and 
malignant thyroid tissue.
24
 This was done with a large, 200 µm source and detector. Our 
first objective with this research is to conduct an in vivo clinical trial with an ESS probe, 
and test if similar findings of ex vivo thyroid tissue can be seen with perfused tissue.  
 In order to conduct an in vivo study, the ESS optical probe must be made to fit 
through the concentric constraint of a standard 23 gauge biopsy needle. The fiber optics 
used in the ex vivo study were too large to meet the constraint of a biopsy needles, so the 
ESS probe needed to be miniaturized.  
 When we have obtained data from the miniaturized in vivo ESS probe, we will 
have to co-register ESS readings with cytology and histology because we want to 
correlate malignant, perfused thyroid tissue with its respective and unique ESS optical 
signature. That way, we can establish and eventually recognize malignant thyroid tissue 
based off of its optical signature. 
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 Lastly, we would like to use the ESS data to discriminate benign from malignant 
nodules through an automated feature analysis. In order to automate this feature analysis 
we need to firmly establish what a malignant spectra looks like by entering and 
correlating approximately 20 malignant thyroid tissues into the study. 
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MATERIALS AND METHODS 
Elastic Scattering Spectroscopy System  
The ESS instrumentation consists of a light source, in this case, a pulsed xenon 
arc lamp, an optical fiber probe, a spectrometer, and a computer to control the various 
components and record the spectra. These pieces of equipment are housed in a small and 
portable unit, seen below in figure 3. 
 
Figure 3: An image of the portable ESS console. 
 
 
 
 
 
 
When a technician presses a button on the ESS console, a short pulse (~7 ms) of 
white light is emitted from the xenon arc lamp (Perkin Elmer, Inc., Fremont, CA) and 
travels through a pair of flexible fiber optic probes. The optical fiber which carries the 
light from the source to the tissue is deemed the source fiber. The optical fiber which 
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carries the light scattered from the tissue back to the spectrometer is deemed the detector 
fiber. A graphic is shown below for clarification.  
 
Figure 4: A graphic of the basic setup of our ESS optical probe. The essential components, a 
computer, xenon lamp, and spectrometer are housed within one portable unit. A pair of fiber 
optics connects the ESS equipment to the biopsy syringe. 
 
 The photons emitted from the source fiber hold one of two fates when they reach 
thyroid tissue. The photons are either absorbed in the thyroid tissue, or scattered about the 
tissue. In the instance where the photon is scattered about, eventually some of the photons 
will reach the detector fiber, travel through it, and be sensed by the spectrometer. The 
photon carries information with it about the size and density of the tissue it just interacted 
with, and will display a spectrum based on the cellular and sub-cellular components of 
the tissue.
26
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 It has been demonstrated in other organs and tissues that ESS is sensitive to 
cellular and subcellular changes in the cell, including most of the features that 
pathologists look for under a microscope when diagnosing a malignant tissue, as well as 
the features associated with malignant transformation. In this sense, ESS is capable of 
providing an “optical biopsy” which is capable of discovering these features in a cell, 
without extracting any cells or cellular matter of the tissue. For this reason, ESS does not 
require multiple passes with a biopsy syringe to provide an accurate diagnosis, unlike the 
current state-of-the-art care with the Bethesda system established in 2007.  
 
Designing the Miniaturized In Vivo ESS Probe 
 Before the probe was miniaturized, theoretical and physical measurements were 
done to study the effect that the change in fiber optic probes would have on the scattered 
light in tissue.
27
 Design priority was given to maintaining the intensity of light 
transmitted through the fiber optics; thus, the source fiber optic was designed to be larger 
than the detector fiber. Through a Monte Carlo simulation of the Mie theory, analysis 
showed that with the concentric constraint of a 23 gauge biopsy syringe, which is found 
to have an approximate diameter of 0.34 mm, it is best to use a 150 µm source fiber, and 
a 100 µm detector fiber. With the smaller fibers used, the cladding, buffer and jacket of 
the fiber were found to be thinner, decreasing the center-to-center distance between the 
fiber optic probes, and making the ESS probe more sensitive to scattering events in the 
tissue. This was an added benefit found during simulation, which enables the in vivo 
optical probe to have an increased sensitivity to scattering events. 
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A smaller optical geometry was designed for the concentric constraint of a 23 
gauge biopsy needle. A 150 micron source and a 100 micron detector were selected for 
the optical fibers of the in vivo probe. Together, the fibers had a 163 micron center-to-
center distance, and were housed in a polyimide casing (Kapton™) that is approximately 
360 microns in diameter. 
A lightweight biopsy syringe was then designed and engineered to house the fiber 
optics of the ESS probe while still maintaining the functionality of a biopsy syringe. The 
unit was engineered to be used with a single hand, just like a typical biopsy syringe. The 
source and detector fibers were threaded through a 23-gauge needle.  The integrated ESS 
biopsy syringe was designed for easy handling and sterilization. The collection and 
recording of a single spectrum takes less than one second, with the data transfer time 
being the limiting factor.  
 
System Calibration  
Before any spectra of the nodules are taken, a reference spectrum was recorded. 
This calibrates the overall system response by recording the diffuse reflectance from a 
spectrally flat diffuse reflector, Spectralon™ (Labsphere, Inc., North Sutton, NH).The 
reference spectrum allows spectral variations in the light source, fiber transmission, 
spectrometer, and fiber coupling to be accounted for. Each consequent nodule or normal 
tissue spectrum was divided by this reference spectrum to obtain the system-independent 
reflectance spectrum of the site being investigated. 
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Miniaturized Probe Validation Study  
A small (n = 16) validation study was done with sequential patients for the newly 
designed in vivo optical geometry. For this experiment, the miniaturized optics (150 
micron source, and 100 micron detector) were used in an ex vivo study under the same 
protocol as the previously published ex vivo ESS optical probe experiment.
1
 The study 
was approved by the Institutional Review Board (IRB) of Boston Medical Center and 
informed consent was obtained prior to their participation from patients with thyroid 
lesions already scheduled to undergo thyroidectomy. ESS data was collected from 
sequential patients scheduled for surgical thyroidectomy, using immediate ex vivo 
thyroidectomy specimens in the frozen section pathology room within 5–10 min of 
surgical removal and prior to the formalin fixation. Specimens were bisected by a 
pathologist at site, and ESS readings were performed on either the most prominent nodule 
or preoperative FNA examined nodules. All nodules were bivalved, and spectra were 
obtained from five sites with five repetitive readings per site per nodule on average, 
depending on the size.  
Normal pathological processing occurred from this point forward. After 
pathological diagnosis has been made, the subjects are de-identified, and the optical 
spectra findings are correlated with the histological criteria for indeterminate thyroid, 
benign thyroid, and thyroid cancer.    
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Data Collection and Spectral Acquisition of the In Vivo Clinical Trial 
For the in vivo experiment of the 150 micron source and 100 micron detector, 
under Boston Medical Center IRB approval, subjects were recruited (n = 103) from the 
Thyroid Clinic at Boston University School of Medicine (BUSM), which is located in 
Boston Medical Center (BMC) under the direction of Dr. Stephanie Lee. Patients 
undergoing a standard FNA of their thyroid gland as a part of their normal clinical care 
were eligible for the study. Prior to participation in the study, the endocrinologist 
obtained informed consent from the patient after detailing the treatment plan, risks, 
benefits, alternatives, cost, etc. The portable instrument was brought into the biopsy room 
and calibrated. The FNA biopsy syringe, with the optical probe inside of it, was placed 
into the neck as per standard FNA protocol, and guided into the thyroid nodule by 
ultrasound imaging. With the help of a technician, the researcher obtained the optical 
spectra by triggering the spectrometer. Five measurements were taken, over three 
seconds, per each unique recording site. Hemorrhage, degenerative cyst and necrotic 
tissues were avoided with the help of ultrasound guidance, and from real-time assessment 
of spectra by the technician during optical biopsy readings. After the spectral data was 
obtained, the optical probe was retracted while cells were aspirated into cytology tubes.  
Normal pathological processing occurred from this point forward. After 
pathological diagnosis has been made, the subjects are de-identified, and the optical 
spectra findings are correlated with the histological criteria for indeterminate thyroid, 
benign thyroid, and thyroid cancer.    
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More patients were recruited in the in vivo study to account for the increasing 
amount of variables when performing in vivo measurements. Each patient’s specimen 
serves as its own control because the biopsy needle passes through normal thyroid tissue 
en route to the thyroid nodule, and during the ex vivo experiments, normal thyroid tissue 
was measured when available. However, spectra from normal/control tissue are not used, 
or needed for optical diagnosis of the suspect tissue.  
 
Subject Inclusion Criteria 
 Subjects were of both genders, ranging from ages 23-84 years old, of all ethnic 
groups speaking English, or Spanish. No children were included in the study. 
Additionally subjects who participated in the ex vivo study were already undergoing a 
thyroidectomy for thyroid nodules, thyroid cancer and thyroid goiter with nodules. For 
the in vivo study, subjects were already undergoing a thyroid biopsy for thyroid nodules, 
thyroid cancer and thyroid goiter with nodules. Only patients already undergoing a 
biopsy for clinical purposes underwent optical biopsy at the same time as their physical 
biopsy. Accrual continues for the in vivo study at the time of this publication.   
 
Subject Exclusion Criteria 
 Subjects with nodules less than 1 cm in size, with infectious diseases or on blood 
thinning medications (i.e. Coumadin) were excluded.  
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Spectral Processing (Co-Registration) 
ESS measurements from a given patient are assigned to a malignant or benign 
category, based on a patient’s individual histopathology report. Each ESS optical 
spectrum was co-registered with the histopathology from the nodule measured. The data 
was then normalized to one so that a visual inspection upon ration analysis could be done 
on the spectra.  
 
Just as a pathologists can detect morphological changes from visual inspection of 
a histopathology slide, those same morphological changes are found in ESS spectra. By 
training an algorithm with approximately 20 perfused malignant thyroid tissues, in vivo, 
we can firmly establish what a malignant spectra looks like to ESS in vivo. Once this 
algorithm is trained, it is expected to perform objective and automated differentiation 
between benign and malignant thyroid tissue in real-time. 
 
Spectral Analysis 
 The raw spectrum collected from each measurement consists of 1,000 detector 
pixels, or data points from wavelength 187 – 873 (nm). The five measurements taken at 
each site were averaged to improve the signal-to-noise ratio. All spectra were then pre-
processed by cropping, smoothing and normalizing before analysis. A diagnostic 
algorithm will be developed based on multidimensional data analysis methods to classify 
the measured spectra. Given the high dimensional nature of the data, a framework 
consisting of dimensionality reduction will be used prior to classification of benign and 
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malignant. Dimensionality reduction will be accomplished using principal component 
analysis (PCA).
28
 For classification, linear support vector mechanisms (SVM)
29,30
, trained 
with the features of benign and malignant ESS spectra were extracted with PCA, and 
were used. Leave-one-out cross-validation was used to obtain estimates of performance 
in the form of sensitivities and specificities. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 22 
 RESULTS 
 An Internal Review Board (IRB) approved clinical study was done at Boston 
Medical Center (BMC) in which 36 patients were enrolled. Before undergoing a 
thyroidectomy, patients consented to have their thyroid tissue measured with a large ex 
vivo ESS probe fitted with a 200 µm source and detector fiber immediately after removal. 
The results of this trial can be seen in table 3.  
 
Table 3: Shows the results of the ex vivo clinical trial with the large ESS optical probe. 
 
 
 
Histopathology 
E
S
S
 
 
Malignant Benign 
Malignant 12 1 
Benign 3 20 
 
 
The ex vivo clinical study revealed that ESS was 95% specific in identifying 
benign from malignant thyroid tissue when compared against the gold standard of 
histopathology.
24
 The ESS probe was found to have a high specificity when used as a 
diagnostic test for thyroid cancer. 
An in vivo IRB approved clinical study was done at BMC in which 108 patients were 
assessed for eligibility and 103 were submitted for analysis. Three patients declined to 
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participate in the research and five patients were excluded from analysis. Out of the 103 
participants enrolled in the study, the average enrolled patient was found to be a 
Caucasian female in her 50’s. 20 of the patients have undergone surgery, and 6 have had 
histopathology-confirmed malignant thyroid tissue.  
 
Table 4: Demographics of the in vivo optical probe study. 
 
 Of the 108 patients assessed for eligibility, three patients declined to participate in 
the study. After the study procedure was explained to the patients, two of the patients 
expressed a fear of needles, and did not want to endure the extra 10-15 seconds to take 
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ESS measurements. One of the patients had already participated in the study, and did not 
want to re-participate in the study. Five patients were excluded from the analysis of the 
study. On two of the patients ESS probes failed to deploy the fiber optic fiber and no 
spectra was attained, and on three of the patients a procedural error barred any spectra 
from being attained. Figure 1 below shows a graphical representation of the in vivo trial 
enrollment.  
 
Figure 5: A flowchart of the in vivo trial enrollment. 
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Figure 6: Shows the plot of averages for nodules that fell into the benign, and malignant 
categories for the previous ex vivo study utilizing a 200 micrometer (µm) source and 200 µm 
detector. 
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Figure 7: Shows the plot of averages for nodules that fell into the benign, and malignant 
categories for the ex vivo study utilizing a miniaturized ESS probe. The probe contained a 150 
micron source and 100 micron detector. 
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Comparison of ex vivo 200/200 to ex vivo 150/100 
 The spectra taken from these two probes were taken with different optical 
geometry. The ex vivo 200/200 probe utilized a 200 µm source and a 200 µm detector. 
The ex vivo 150/100 probe utilized a 150 µm source, and a 100 µm detector. There seems 
to be a greater differentiation between the benign and malignant spectra from the ex vivo 
150/100 probe, when compared to the ex vivo 200/200 probe. 
 
Comparison of ex vivo 150/100 to in vivo 150/100 
Spectra collected from the two probes consisting of the same optical geometry 
have similar looking spectra. The greatest variance between benign and malignant spectra 
for both the ex vivo 150/100 and the in vivo 150/100 can be noted at the lower 
wavelengths from approximately 300 – 400 nm and at the higher wavelengths from 
approximately 600 – 800 nm.  
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Figure 8: Shows the plot of averages for nodules that fell into the benign and malignant 
categories for the in vivo study utilizing a miniaturized ESS probe. The probe contained a 150 
micron source and 100 micron detector. 
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Figure 9: Demonstrates what the real-time raw data looks like when collecting measurements 
with the ESS in vivo biopsy syringe. The plot shows measurements taken in two separate regions 
of a nodule. Location #1 is taken in normal thyroid tissue.  
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Figure 10: Example data taken from a cystic thyroid nodule with the ESS in vivo biopsy syringe. 
The plot shows measurements are taken in three separate regions of a nodule, and show a clear 
differentiation between the spectra of normal and cystic tissue. 
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Figure 11: Example measurement of a thyroid location with hemoglobin saturation, as indicated 
by the large trough at approximately 420 nm. 
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DISCUSSION 
Preliminary in vivo results of the ESS optical biopsy syringe has been consistent 
with our ex vivo initial trial. Upon visual inspection of the normalized spectra, one can 
see a differentiation between the benign and malignant spectra, especially at the lower 
wavelengths. Upon viewing the electromagnetic spectrum (see figure 12 below) it is 
evident that the regions of greatest variability between the benign and malignant spectra 
occur at the lower wavelengths correlating with ultraviolet light. 
 
Figure 12: A figure showing visible light in relation to the complete electromagnetic 
spectrum. Figure was downloaded from “what is the electromagnetic spectrum at 
http://scimad.com”. 
 
 The changes noted in the results to can be traced to the regions of ultraviolet light 
(320 to 400 nm) and are consistent with Rayleigh scattering, which assumes that photons 
are elastically scattered.
31
 Looking at figures 6, 7 and 8  an increasing differentiation 
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between the benign and malignant spectra at the lower wavelengths is noted. The data 
suggests that as the optical geometry of the probe gets smaller, the probe becomes more 
sensitive to Rayleigh scattering.  
 During the miniaturization process of the probe, a smaller optical geometry was 
utilized. Instead of the original 200 µm source and 200 µm detector fiber used in the ex 
vivo probe, both a smaller source, at 150 µm and a smaller detector, at 100 µm were 
utilized. Not only were the inner diameters of the fibers smaller than the original probe, 
but the cladding, and the silicone coating of the fiber, were also thinner. This allowed the 
source and detector fiber to be oriented closer to one another. It has been found through 
both empirical and theoretical measurements that a smaller optical geometry allows for 
increased sensitivity to photon scattering.
27
 This could account for the greater 
differentiation seen with the smaller optical geometry.  
 Visual inspection of the averaged, normalized spectra from both the malignant 
and benign thyroid tissues of the in vivo ESS optical probe suggest that there is a unique 
optical signature associated with a specific diagnosis of thyroid cancer. Although it is too 
early to perform statistical analysis to increase the validity, early results of this 
experiment suggest that ESS is capable of accurately differentiating and diagnosing 
thyroid tissue in real-time.  
Additional benefits of the real-time feedback that ESS provides are that it is 
capable of detecting the contents of a thyroid nodule, including but not limited to cystic 
fluid, micro and macro calcifications, and hemoglobin content. This information carries 
with it the potential to increase the diagnostic capabilities of an FNAB. This can ensure 
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that a biopsy syringe is actually inside of the nodule, which is extremely helpful when 
there aren’t well-defined margins on smaller, sub-centimeter nodules which require a 
FNAB. 
 While conducting the clinical trial, it was seen that the raw spectra for normal 
thyroid tissue (figure 9) are noticeably different than those of cystic fluid (figure 10). 
Cystic fluid can often be found in thyroid nodules, although in order to attain a diagnostic 
cytology report, a clinician must biopsy solid tissue within the nodule.
32
 These finding 
suggests that an ESS integrated biopsy syringe would not only be able to increase the 
specificity of a FNAB through analyzing the spectra for a malignant tissue, but can also 
increase the quality of cytology, leading to better diagnostic value for the gold standard.  
Reviewing the compiled FNAB classifications of the patients entered into the 
study show a smaller percentage of insufficient biopsies than those reported in the 
literature. Looking at table 4 one can see that 3 out of 103 patients, or approximately 3% 
received an insufficient biopsy with the ESS integrated optical biopsy syringe, as 
opposed to 10%, the average number of insufficient biopsies reported in the literature.
1
  
The ESS integrated biopsy syringe was also found to be sensitive to calcifications 
within nodules. Thus far in the study, only a visual inspection of the normalized data has 
been done. In the future, a study of the intensities of the spectra could provide more 
diagnostic information on the thyroid tissue biopsied with the ESS probe, and potentially 
differentiate between types of thyroid cancer.  
ESS measures the reflection of light through absorbance units. The more light 
emitted from the source fiber, the more light will be reflected, regardless of the tissue 
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being studied. The amplitude of the spectra, in conjunction with the shape of the spectra, 
could tell an endocrinologist important information about the tissue of interest. It is 
established that calcification within or around a thyroid nodule can increase the chances 
of a malignant thyroid nodule, but these features aren’t always readily visible during an 
ultrasound.
33
 With ESS, it has been seen that calcium will reflect much more light than 
benign or malignant thyroid tissue. In figure 9 it was noted that location 2 was confirmed 
to be a site of calcification. Four times the amount of light, or pulses were emitted in the 
normal tissue, known to be location 1, than in location 2, the site of calcification, 
however both spectra utilized the full dynamic range. Therefore, by studying the 
amplitude of the spectra, and the amount of pulses released from the light source, ESS 
provides one with the ability to measure another unique and distinguishing property of 
tissue, absolute intensities. 
Lastly, it was noted from the ESS spectra that hemoglobin saturation can be 
indicated by a large absorption (trough) at approximately 420 nm. For reference, figure 
11 shows an example of an ESS measurement taken at a location with hemoglobin 
saturation. When these measurements are made, in real-time, a technician can advise an 
endocrinologist to move to another location within the nodule, and can increase the 
probability of attaining a diagnostic biopsy. 
Due to the fact that there are currently six histopathology-confirmed malignancies 
entered into the study at the time of writing this thesis, an automated algorithm was not 
developed to diagnose the thyroid tissue measured with ESS. Before such an algorithm is 
developed, a malignant ESS spectrum must be firmly established with approximately 20 
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samples of perfused thyroid tissue. With such a large variation between the malignant and 
benign thyroid spectra seen in figure 8 the current data is encouraging, and suggests that 
such an automated algorithm can be easily incorporated into the data collection software. 
In the future, we hope that with little training, a technician can help to guide a biopsy 
syringe to diagnostically rich portion of the nodule, and classify a nodule from a point-
measurement, filling the role of a pathologist. 
Preliminary results of this study indicate that future applications of this 
technology would be beneficial in surgical removal of cancers of embedded, hard-to-
reach organs. Surgical margins on pancreatic cancer would be one of the most logical 
applications for this technology to ensure in real-time that all of the malignant tissue is 
excised during an operation. 
Manufacturing the ESS integrated optical biopsy syringe has cost approximately 
two hundred dollars, with one hundred and sixty dollars going towards labor in milling 
the parts for the probe. Upon large-scale production, labor costs would be drastically 
decreased. The miniaturized ESS probe was found to be easily adopted by 
endocrinologists in the clinic, due to the probe’s design, which is similar to that of a 
typical biopsy syringe. The ESS integrated biopsy syringe is also capable of being 
decontaminated and sterilized, and therefore can be reused.  
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Figure 13: A picture of the 2
nd
 generation ESS integrated biopsy syringe. 
 
There is an unmet clinical need for a more accurate method to diagnose thyroid 
cancer. Currently, there is no definitive way to determine whether a thyroid nodule is 
benign or malignant when cytology yields an indeterminate result. Preliminary data from 
this study suggests that ESS could potentially serve this unmet need in real-time.  
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CONCLUSION 
 ESS spectroscopy was found to be successfully integrated into the lumen of a 23 
gauge biopsy needle. Preliminary in vivo results of this experiment are consistent with the 
previous clinical trial conducted with Suh et al.
24
 The data suggests that there is a unique 
ESS optical signature which corresponds to benign and malignant thyroid tissue. This 
data from ESS carries the potential to reduce the amount of diagnostic surgeries done for 
the most common endocrine malignancy, thyroid cancer. This could potentially save 
thousands of dollars on thyroid surgery, as well as the life-long dependence on thyroid 
hormones, and increase the quality of life for patients found to have a thyroid nodule.  
 The data collected thus far in the study is encouraging. The goal of this research is 
to create an improved diagnosis for thyroid cancer. We hope that this research will 
provide the technology necessary to create a single needle biopsy that will form a better 
diagnosis for patients with thyroid nodules, and provide a better operation for those who 
have thyroid cancer, while avoiding operations for those who don’t.  
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